The Compounding Pharmacy Question

For most of the history of the profession, a pharmacy was a place where medicines were made. The apothecary took raw materials and a physician's instruction and produced, that afternoon, a single preparation for a single named person. Everything about the modern picture — the sealed carton, the identical tablet, the batch number, the manufacturer in another country — is a recent overlay on a much older practice, and that older practice never went away. It is called compounding, and in every developed pharmaceutical system it survives as a lawful, ordinary and largely uncontroversial part of what pharmacists do.

It survives because the mass-manufactured supply cannot cover everything. A child who cannot swallow a tablet needs it as a suspension. A patient allergic to a dye or a preservative in the commercial formulation needs a version without it. A dose exists on the market at 50 milligrams and the person in front of you needs 12. A hospital pharmacy fills syringes from a bulk vial for the ward round. None of this involves a new drug or a new claim; it involves adapting an existing, approved medicine to a person the industrial process did not anticipate 4. The question that has taken a century to answer is where that ends.

An ambiguity nobody resolved

The regulatory difficulty is easy to state and was very hard to fix. A pharmacist making one suspension for one child is obviously practising pharmacy, and pharmacy is supervised by pharmacy boards, not by drug approval agencies. A factory making ten thousand identical sterile vials and shipping them nationwide is obviously manufacturing, and manufacturing requires approval, inspection and compliance with manufacturing-quality regulations. Between those two poles there is a continuum, and for most of the twentieth century no line was drawn on it.

An attempt was made in 1997, when American legislation added a section setting out conditions under which compounded preparations would be exempt from the approval, labelling and manufacturing-practice requirements that apply to drugs. But the section also restricted advertising and solicitation, and in 2002 the Supreme Court struck those restrictions down on free-speech grounds. What remained was contested: some courts held the entire section fell with the struck provisions, others held the rest survived, and the resulting split meant the applicable law genuinely depended on which federal circuit a compounder sat in 3. Meanwhile the sector grew, and some of it grew into something that looked a great deal like manufacturing.

Framingham, autumn 2012

In September 2012 a hospital in Tennessee reported a patient with fungal meningitis, an unusual diagnosis in someone with no obvious reason to have it. State and federal investigators traced the case, and then a growing cluster of cases, to preservative-free methylprednisolone acetate injected into the epidural space for back pain. The product had been supplied by a single compounding pharmacy in Framingham, Massachusetts. The first published series described the Tennessee outbreak and identified the organism, an environmental mould rarely seen in human disease 1.

The scale became clear over the following weeks. Three contaminated lots had been distributed to healthcare facilities in twenty-three states, exposing roughly fourteen thousand people. The eventual national tally ran past seven hundred and fifty cases and past sixty deaths, with meningitis, strokes from basilar artery involvement, and localised joint and spinal infections among the presentations 2. It became one of the largest healthcare-associated outbreaks in American history, caused not by a resistant organism or a novel pathogen but by contaminated stock from one facility.

What the investigation exposed was precisely the ambiguity described above. The facility was licensed as a pharmacy and supervised as one. It was also producing sterile injectables in volume and shipping them across state lines to institutional customers, in many cases without patient-specific prescriptions. Under the rules as they stood, the entity best equipped to inspect a sterile manufacturing operation had unclear authority over it, and the entity with clear authority was a state pharmacy board with neither the remit nor the resources for the job 3. Nobody had designed that arrangement. It was what the unresolved boundary looked like in practice.

The statute that followed

The Drug Quality and Security Act was signed in November 2013, thirteen months after the first case. Its first title created a structure that is now the reference model internationally, and its logic is a compromise: rather than trying to define the point on the continuum where compounding becomes manufacturing, it offers two named places to stand and lets compounders choose.

Both tiers are conditional. The exemptions apply only where a list of statutory conditions is satisfied, and one of those conditions has turned out to matter enormously. A compounded preparation may not ordinarily be essentially a copy of a commercially available approved drug — the point of compounding being to fill gaps the market leaves, not to duplicate what the market already supplies. But the statute suspends that restriction for a drug appearing on the regulator's official shortage list. If the approved product is not actually available, it is not, for these purposes, commercially available, and the copy prohibition lifts.

The two-tier model has been influential well beyond the country that wrote it, partly because most systems had the same unresolved boundary and no comparable prompting disaster. European pharmaceutical law had long dealt with the question by exempting two narrow traditional categories from the marketing-authorisation requirement: the magistral formula, prepared in a pharmacy in accordance with a prescription for an individual patient, and the officinal formula, prepared in a pharmacy according to a pharmacopoeia and supplied directly to that pharmacy's own patients. Both definitions are tight, both are anchored to the pharmacy that dispenses, and neither contemplates industrial-scale sterile production for distant institutional customers. Where European regulators have confronted large-scale preparation, they have generally done so through hospital-pharmacy and manufacturing-licence rules rather than by building a new statutory tier.

What all these frameworks share is the shape of the underlying compromise. Compounded preparations are permitted to exist without pre-market approval because approval is impossible for a preparation made once, for one person, on a Tuesday afternoon. The trade is that the preparation must stay small, particular and clinically justified — and the moment it stops being those things, the argument for the exemption evaporates. Every rule in the area is an attempt to police that trade, and every rule has been written after somebody stopped honouring it.

The window, and the day it shut

In 2022 the incretin-based medicines for type 2 diabetes and obesity entered shortage. Demand had outrun a manufacturing base built for a much smaller market, and the products went onto the official shortage list. That listing did what the statute says it does: it suspended the copy restriction, and compounding of those molecules became lawful under the 2013 conditions, in both tiers. Over roughly two years an entire sector organised itself around that opening, at very considerable scale.

Then the manufacturing base caught up. The regulator determined that the tirzepatide shortage was resolved in December 2024 and that the semaglutide shortage was resolved in February 2025, and with those determinations the condition that had opened the window ceased to be true. Because a hard cut-off would have stranded product and patients mid-course, the agency published wind-down dates instead: enforcement discretion for the traditional tier running to late April 2025 and for registered outsourcing facilities to late May 2025, with earlier dates for tirzepatide 5. Trade bodies representing compounders sued to challenge the shortage determinations; the courts declined to grant preliminary relief, and the dates held. The regulator subsequently moved to place those molecules on the list of substances excluded from bulk compounding by outsourcing facilities, which would close the route by a second and more permanent mechanism.

It is tempting to read that episode as an enforcement story, and it was not one. Nothing was uncovered, nobody was found to have acted improperly, and no scandal precipitated the end. A statutory condition became true in 2022 and stopped being true in 2024 and 2025, and a large commercial activity that existed entirely because of that condition ended with it. The window was never a permission granted to compounders. It was a shortage provision doing its job in both directions — opening when supply failed, and closing when supply recovered.

Which returns the story to where the cluster keeps arriving. The 2013 statute is a good statute, carefully drafted and internationally influential, and it exists because sixty-four people died of injections of a steroid that should have been sterile. The shortage provision inside it is elegant, and its most consequential application to date was one nobody drafting it in 2013 had in mind. Rules in this field are written backwards from accidents, and then applied forwards to situations their authors never imagined. Both halves of that sentence are worth holding on to.